1092580-91-0

Basic information

• Product Name: 1H-pyrrolo[2,3-b]pyridine, 5-broMo-, 7-oxide
• Synonyms: 1H-pyrrolo[2,3-b]pyridine, 5-broMo-, 7-oxide
• CAS NO: 1092580-91-0
• Molecular Formula: C7H5BrN2O
• Molecular Weight: 213.0314
• Mol File: 1092580-91-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.87
• CAS DataBase Reference: 1H-pyrrolo[2,3-b]pyridine, 5-broMo-, 7-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-pyrrolo[2,3-b]pyridine, 5-broMo-, 7-oxide(1092580-91-0)
• EPA Substance Registry System: 1H-pyrrolo[2,3-b]pyridine, 5-broMo-, 7-oxide(1092580-91-0)

Safety Data

• Hazardous Substances Data: 1092580-91-0(Hazardous Substances Data)

Usage

Compound type

Heterocyclic compound

Structure

Fused 6-membered pyrrolo ring and 5-membered pyridine ring

Bromine atom position

5th position

Oxygen group position

7th position

Unique chemical properties

Presence of bromine atom and oxygen group at the 7th position

Potential applications

Medicinal chemistry, pharmaceutical research, and as a building block in the synthesis of biologically active compounds

Therapeutic properties

Potential therapeutic properties due to structural features

Upstream product

• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 

Relevant articles and documents

Design and synthesis of potent RSK inhibitors

Utilizing the already described 3,4-bi-aryl pyridine series as a starting point, incorporation of a second ring system with a hydrogen bond donor and additional hydrophobic contacts yielded the azaindole series which exhibited potent, picomolar RSK2 inhib

CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS

The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER

The present application relates to a compound of Formula I, or a salt, hydrate or solvate thereof, as defined herein. The present compounds are found to have pharmacological effects, particularly at MRCK. Further provided are pharmaceutical compositions comprising said compounds. The present invention also relates to the use of these compounds as therapeutic agents, in particular, for the treatment and/or prevention of proliferative diseases, such as cancer.